Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 1.00 |
| ▸ | PPP6C | O00743 | 1/20 | 1.00 |
| ▸ | PPP1CC | P36873 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | PPP5C | P53041 | 1/20 | 1.00 |
| ▸ | PPP2CA | P67775 | 1/20 | 1.00 |
| ▸ | PPP2R5A | Q15172 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Calyculin A SCHEMBL4295478 | 1.00 | PTPN1 (1.00) | PTPN1PPP6CPPP1CCHTTPPP5C | |
| Calyculin A SCHEMBL82924 | 1.00 | PTPN1 (1.00) | PTPN1PPP6CPPP1CCHTTPPP5C | |
| Calyculin B SCHEMBL29809573 | 1.00 | PTPN1 (1.00) | PTPN1PPP6CPPP1CCHTTPPP5C | |
| Calyculin A SCHEMBL4299349 | 1.00 | PTPN1 (1.00) | PTPN1PPP6CPPP1CCHTTPPP5C | |
| Calyculin A SCHEMBL82925 | 1.00 | PTPN1 (1.00) | PTPN1PPP6CPPP1CCHTTPPP5C | |
| Calyculin A SCHEMBL21408822 | 1.00 | PTPN1 (1.00) | PTPN1PPP6CPPP1CCHTTPPP5C | |
| SCHEMBL15919331 | 0.95 | PTPN1 (0.91) | PTPN1PPP6CPPP1CCHTTPPP5C | |
| Calyculin SCHEMBL1443597 | 0.94 | PTPN1 (1.00) | PTPN1PPP6CPPP1CCHTTPPP5C | |
| Calyculin SCHEMBL29536011 | 0.94 | PTPN1 (1.00) | PTPN1PPP6CPPP1CCHTTPPP5C | |
| Calyculin SCHEMBL4291014 | 0.94 | PTPN1 (1.00) | PTPN1PPP6CPPP1CCHTTPPP5C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3966344-B1 | KINASE SCREENING ASSAYS | UNIV NEWCASTLE (GB) | 2025-06-25 | — | — | EP | claimed |
| US-20220323344-A1 | TRANSDERMAL PENETRATION BY MODULATING EPITHELIAL JUNCTIONS | DYVE BIOSCIENCES, INC. | 2022-10-13 | — | — | US | claimed |
| EP-4069210-A1 | TRANSDERMAL PENETRATION BY MODULATING EPITHELIAL JUNCTIONS | Dyve Biosciences, Inc. (US) | 2022-10-12 | — | — | EP | claimed |
| US-20240398814-A1 | KRAS INHIBITOR AND HDAC INHIBITOR COMBINATION FOR THE TREATMENT OF CANCER | NORTHWESTERN UNIVERSITY | 2024-12-05 | — | — | US | disclosed |
| US-20240279234-A1 | KINASE INHIBITORS AND RELATED METHODS OF USE | UTI LIMITED PARTNERSHIP (CA) | 2024-08-22 | — | — | US | disclosed |
| CN-118159644-A | Method for producing enteroendocrine cells, enteroendocrine cells derived from pluripotent stem cells, medium or medium kit, and use thereof | 富士胶片株式会社 | 2024-06-07 | — | — | CN | disclosed |
| US-11999737-B2 | Kinase inhibitors and related methods of use | DUKE UNIVERSITY (US) | 2024-06-04 | — | — | US | disclosed |
| US-11834401-B2 | Treating and preventing diseases by modulating cell mechanics | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| WO-2023152504-A1 | AN AFFINITY-DIRECTED PHOSPHATASE SYSTEM FOR TARGETED PROTEIN DEPHOSPHORYLATION | UNIVERSITY OF DUNDEE (GB) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023074648-A1 | METHOD FOR PRODUCING INTESTINAL ENDOCRINE CELLS, PLURIPOTENT STEM CELL-DERIVED INTESTINAL ENDOCRINE CELLS, MEDIUM OR MEDIUM KIT, AND USE OF THE SAME | 富士フイルム株式会社 | 2023-05-04 | — | — | WO | disclosed |
| CN-110237257-B | Application of Ube3a ubiquitinated PP2A activator PTPA in treatment of Angel syndrome and autism | 中国科学院脑科学与智能技术卓越创新中心 | 2023-01-03 | — | — | CN | disclosed |
| CN-113943743-B | Application of SlLYK4 gene in enhancing fungal disease resistance of tomato | 浙江大学 | 2022-10-28 | — | — | CN | disclosed |
| US-20220323344-A1 | TRANSDERMAL PENETRATION BY MODULATING EPITHELIAL JUNCTIONS | DYVE BIOSCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
| EP-4069210-A1 | TRANSDERMAL PENETRATION BY MODULATING EPITHELIAL JUNCTIONS | Dyve Biosciences, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
| CN-114929208-A | Transdermal penetration by modulation of epithelial junctions | 黛芙生物科学公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-114126666-A | Methods for treating subjects with pre-existing immunity to viral transfer vectors | 西莱克塔生物科技公司 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279234-A1 | KINASE INHIBITORS AND RELATED METHODS OF USE | DAPK2, DAPK1, DAPK3 | PTPN1 871/4885PPP6C 341/4885PPP1CC 948/4885 |
| US-20240398814-A1 | KRAS INHIBITOR AND HDAC INHIBITOR COMBINATION FOR THE TREATMENT OF CANCER | KRAS, HRAS, HDAC1 | PTPN1 1272/4885PPP6C 1524/4885PPP1CC 1829/4885 |
| US-11834401-B2 | Treating and preventing diseases by modulating cell mechanics | PKD1, MMP11, MMP13 | PTPN1 3257/4885PPP6C 236/4885PPP1CC 2278/4885 |
| US-11999737-B2 | Kinase inhibitors and related methods of use | DAPK2, DAPK1, DAPK3 | PTPN1 871/4885PPP6C 341/4885PPP1CC 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.